+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06830863

Study of Topical ATR04-484 Compared to Placebo for Treating Moderate to Severe EGFR Inhibitor-Related Skin Rash

Led by Azitra Inc. · Updated on 2026-10-13

32

Participants Needed

6

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying ATR04-484, a topical treatment, to see if it can help with skin rash caused by EGFR inhibitor therapy in adults with moderate to severe skin toxicity mainly on the face. This randomized, blinded Phase 12 trial compares ATR04-484 to a similar ointment without the active ingredient vehicle to assess safety, tolerability, and early signs of effectiveness. The study is sponsored by Azitra Inc. Participants are divided into two groups. The first small group receives a single 4 g application of ATR04-484 or vehicle daily to affected areas like the face, chest, and back, followed by a 7-day observation. They may then continue daily applications for 28 more days. A second larger group will receive daily 4 g applications for 28 days. After treatment, all participants are followed for 28 days to monitor effects. During the study, participants apply the ointment once daily and visit the clinic regularly for evaluations and sample collections. Researchers will assess safety and tolerability as the main outcome over 57 days. They will also measure skin rash severity, itchiness, pain, quality of life, and how much ATR04-484 is absorbed. The total participation involves treatment and follow-up periods to closely monitor participants responses and well-being.

CONDITIONS

Brief Title

A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity

Research Team

M

Mary Spellman, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here